Saxagliptin for type 2 diabetes

Código QR

Saxagliptin for type 2 diabetes

Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Chacra
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	saxagliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0d1ee3178ca44542a77f397f616f61e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

The new drug saxagliptin is now registrated in Russia
por: Editorial team Diabetes Mellitus
Publicado: (2010)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh S, et al.
Publicado: (2016)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
por: Cosenso-Martin LN, et al.
Publicado: (2020)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi T, et al.
Publicado: (2020)

Saxagliptin for type 2 diabetes
por: Antonio R Chacra, et al.
Publicado: (2010)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
por: Gul O, et al.
Publicado: (2019)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
por: Woodman OL, et al.
Publicado: (2019)

Synergistic antidiabetic activity of Taraxacum officinale (L.) Weber ex F.H.Wigg and Momordica charantia L. polyherbal combination
por: Nithiyaa Perumal, et al.
Publicado: (2022)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa H, et al.
Publicado: (2020)

Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
por: Lanna C, et al.
Publicado: (2019)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
por: Gagik R. Galstyan, et al.
Publicado: (2016)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Baptist Gallwitz
Publicado: (2010)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
por: Marina Vladimirovna Shestakova
Publicado: (2011)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley RE
Publicado: (2014)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats
por: Mi J, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng F, et al.
Publicado: (2019)